FRANKLIN LAKES, N.J.,
Sept. 26, 2017 /PRNewswire/
-- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading
global medical technology company, today announced the
launch1 of the first automated phenotypic test to detect
and classify carbapenemase-producing organisms (CPO). Available as
part of the BD Phoenix™ automated microbiology system
in Europe, the new
BD Phoenix™ CPO detect test will help
hospitals identify and contain infections caused by CPO, while
potentially combating an increase in antimicrobial resistance
(AMR).
According to the Centers for Disease Control and Prevention
(CDC), CPOs, specifically carbapenem-resistant
Enterobacteriaceae (CRE), represent a prominent AMR threat
to public health because these dangerous microbes may be resistant
to nearly all available antibiotics.2 These organisms
are also on the World Health Organization (WHO) priority pathogen
list as critical threats to public health3. Reported
rates of mortality associated with certain CPO infections vary
widely from 22 to 72 percent4. When CPOs are detected,
rapid implementation of infection prevention measures are needed to
prevent further transmission.
The BD Phoenix CPO detect test, included on BD
Phoenix™ gram-negative panels, identifies
CPOs and provides the Ambler classification of the enzyme produced.
In contrast to conventional phenotypic methods for CPO detection
that can take up to 96 hours, the BD Phoenix™ CPO
detect test can detect CPOs accurately in under 36 hours.
The test allows hospitals and laboratories to categorize
microbial resistance facilitating the rapid implementation of
infection control procedures and the selection of appropriate
antibiotics. It provides information that can be used to support
hospitals in managing their antimicrobial stewardship programs more
effectively.
"The BD Phoenix CPO detect test is a completely new type of
phenotypic test, and its range of capabilities is unmatched by all
currently marketed tests," said Kenneth S.
Thomson, PhD, FIDSA, FAAM, FASM clinical professor of
Pathology and Laboratory Medicine, University
of Louisville School of Medicine. "It represents a
significant advance in meeting an important clinical need."
Fully integrated within BD Phoenix panels, the new BD Phoenix
CPO detect test enables laboratories to offer a more comprehensive
antimicrobial susceptibility test profile while improving
laboratory process efficiency. The test is available in two
configurations, offering flexibility to customers; a combo panel
that detects the presence of CPOs, and the BD
Phoenix™ emerge panel that detects the
presence of CPOs and if positive, provides the Ambler
classification of the carbapenemase.
"The BD Phoenix CPO detect test gives laboratories an accurate
and cost-effective method to rapidly identify CPOs and support
patient management," said Steve
Conly, vice president of Microbiology for BD. "Along with
the BD Phoenix™ M50, this first-to-market phenotypic
automated test to detect CPOs, expands BD's portfolio of solutions
for identification and antimicrobial susceptibility testing
(ID/AST) and is another example of the company's commitment to
combating AMR."
Visit bd.com/ds for more information.
About BD Phoenix™
The BD Phoenix™ automated identification and
susceptibility testing system is part of BD's line of products for
rapid, accurate and reliable detection of microbial organisms.
Using BD Phoenix products, laboratories can identify organisms and
understand emerging antimicrobial resistance, improving
communication with clinicians to improve both patient management
and antibiotic stewardship.
About BD
BD is a global medical technology company that is advancing the
world of health by improving medical discovery, diagnostics and the
delivery of care. BD leads in patient and healthcare worker safety
and the technologies that enable medical research and clinical
laboratories. The company provides innovative solutions that help
advance medical research and genomics, enhance the diagnosis of
infectious disease and cancer, improve medication management,
promote infection prevention, equip surgical and interventional
procedures, optimize respiratory care and support the management of
diabetes. The company partners with organizations around the world
to address some of the most challenging global health issues. BD
has nearly 50,000 associates across 50 countries who work in close
collaboration with customers and partners to help enhance outcomes,
lower health care delivery costs, increase efficiencies, improve
healthcare safety and expand access to health. For more information
on BD, please visit bd.com.
Contacts:
|
|
|
|
Gwen
Gordon
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.812.3724
|
201.847.5378
|
gwen.gordon@bd.com
|
monique_dolecki@bd.com
|
____________________________________
1 Currently available for sale in Europe. Product not available for sale in the
US.
2 Centers for Disease Control and Prevention (CDC).
Antibiotic Resistance Threats in the
United States, 2013. Atlanta: CDC; 2013.
3 World Health Organization. Global Priority List of
Antibiotic-Resistant Bacteria to Guide Research, Discovery, and
Development of New Antibiotics. February
2017.
http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1.
Accessed March 20, 2017.
4 Tumbarella, M. et al. (2015) J Antimicrob
Chemother 70: 2133-2143
View original
content:http://www.prnewswire.com/news-releases/bd-expands-efforts-to-combat-antimicrobial-resistance-with-new-diagnostic-test-in-europe-300525357.html
SOURCE BD (Becton, Dickinson and Company)